Prospects for the prevention and control of gram-negative nosocomial infections.
Nosocomial infections of bacterial origin continue to be a leading cause of morbidity and mortality among virtually all hospitalized patient populations. It is estimated that nearly 5% of all hospitalized individuals will acquire an infection during their stay. Approximately 3% of nosocomial infections will contribute to an eventual fatal outcome. Preeminent among nosocomial pathogens are the aerobic Gram-negative bacilli, with Escherichia coli, Pseudomonas aeruginosa and Klebsiella spp. being the causative agents for the majority of life-threatening infections. This review describes the current situation and future prospects for combatting these infections.
D001424:Bacterial Infections / Q000517:prevention & control*; D001428:Bacterial Vaccines; D002986:Clinical Trials as Topic; D003428:Cross Infection / Q000517:prevention & control*; D004926:Escherichia coli; D006017:Glycolipids / Q000276:immunology; D006801:Humans; D007709:Klebsiella; D011550:Pseudomonas aeruginosa
D001428:Bacterial Vaccines; D006017:Glycolipids